我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
55
12 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
进行中（未招募）
2
3.6%
已完成
9
16.4%
尚未招募
10
18.2%
招募中
21
38.2%
Unknown
13
23.6%
暂无批准数据
• SHR-A1921, an antibody-drug conjugate, demonstrated a 42.3% overall response rate in platinum-resistant ovarian cancer patients at a 3.0 mg/kg dose. • The disease control rate reached 100% in patients treated with SHR-A1921 at 3.0 mg/kg, with a median duration of response of 9.9 months. • Manageable safety profiles were observed across both 3.0 mg/kg and 2.0 mg/kg dosing regimens of SHR-A1921 in heavily pretreated patients. • A phase 3 trial is underway to compare SHR-A1921 with chemotherapy in platinum-resistant epithelial ovarian cancer.
